Abstract:OBJECTIVE:The aim of this study was to explore the effect of long non-coding ribonucleic acid (lncRNA) AK125437 on rats with postmenopausal osteoporosis via the mitogen-activated protein kinase (MAPK) pathway. MATERIALS AND METHODS:A total of 36 Sprague-Dawley rats were randomly divided into three groups, including normal group, model group, and an inhibitor group, with 12 rats in each group. Only ovaries were exposed in normal group. The postmenopausal osteoporosis model was established in model group. Meanwhile, the intervention was performed with inhibitor for 3 months after modeling in inhibitor group, followed by sampling. The expression of receptor activator of nuclear factor kappa-B ligand (RANKL) was detected via immunohistochemistry. The protein expression level of phosphorylated p38 (p-p38) MAPK was determined via Western blotting (WB). Furthermore, the expression level of lncRNA AK125437 and the content of serum estradiol were determined via quantitative Polymerase Chain Reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA), respectively. In addition, bone mineral density was measured using dual-energy X-ray bone mineral absorptiometer. RESULTS:Immunohistochemistry results indicated that model group and inhibitor group had notably up-regulated positive expression level of RANKL than normal group (p<0.05), which was remarkably lower in inhibitor group than model group (p<0.05). Western blot results showed that compared with normal group, the protein expression level of p-p38 MAPK was substantially elevated in model and inhibitor groups (p<0.05). Meanwhile, the protein expression level of p-p38 MAPK was markedly lower in inhibitor group than that in model group (p<0.05). According to qPCR results, the expression level of lncRNA AK125437 was significantly up-regulated in both model group and inhibitor group compared with normal group, showing statistically significant differences (p<0.05). However, no significant differences were observed between model group and inhibitor group (p>0.05). ELISA results revealed that model group and inhibitor group had markedly lower estradiol content than normal group (p<0.05). There was no statistically significant difference in the content of estradiol between the two groups (p>0.05). According to the measurement results of bone mineral density, compared with normal group, bone mineral density was notably lower in model group and inhibitor group (p<0.05). Furthermore, it was markedly higher in inhibitor group than that of model group (p<0.05). CONCLUSIONS:LncRNA AK125437 affects the bone mineral density of rats with postmenopausal osteoporosis by activating the MAPK pathway.

A novel long noncoding RNA AK016739 inhibits osteoblast differentiation and bone formation

Long noncoding RNA AK039312 and AK079370 inhibits bone formation via miR-199b-5p

Silencing Of Lncrna Ak045490 Promotes Osteoblast Differentiation And Bone Formation Via Beta-Catenin/Tcf1/Runx2 Signaling Axis

LncRNA AK077216 promotes RANKL‐induced osteoclastogenesis and bone resorption via NFATc1 by inhibition of NIP45

Osteogenic differentiation induced by bone morphogenetic protein 2 and long non-coding RNA AK007000

A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs

ALX1-transcribed LncRNA AC132217.4 Promotes Osteogenesis and Bone Healing Via IGF-AKT Signaling in Mesenchymal Stem Cells

Long non-coding RNAs in bone formation: Key regulators and therapeutic prospects

Long noncoding RNA Lnc-DIF inhibits bone formation by sequestering miR-489-3p

Advances of long non-coding RNAs in osteoclast differentiation and osteoporosis

The Long Non-coding RNA-ORLNC1 Regulates Bone Mass by Directing Mesenchymal Stem Cell Fate

LINC00963 Represses Osteogenic Differentiation of hBMSCs via the miR-10b-5p/RAP2A/AKT Axis

Silencing long noncoding RNA colon cancer-associated transcript-1 upregulates microRNA-34a-5p to promote proliferation and differentiation of osteoblasts in osteoporosis

Lncrna Expression Profiles and the Negative Regulation of Lncrna-Nommut037835.2 in Osteoclastogenesis.

The long noncoding RNA lnc-ob1 facilitates bone formation by upregulating Osterix in osteoblasts

Effect of Lncrna AK125437 on Postmenopausal Osteoporosis Rats Via MAPK Pathway.

Role of long non-coding RNA in osteoblast differentiation of C3H10T1/2 cells induced by bone morphogenetic protein-2

Identification of long non‐coding RNAs expressed during the�osteogenic differentiation of human bone marrow‐derived mesenchymal stem cells obtained from patients with ONFH

[Kcnq1ot1 Promotes Osteogenic Differentiation and Suppresses Osteoclast Differentiation].

The Role of Micro RNA and Long-Non-Coding RNA in Osteoporosis

CTD-2555A7.2 Promotes Bone Formation with LncRNA-specific Cascade Amplification Strategy